Skip to main content

Chemicon and Australian Stem Cell Center to Commercialize Stem Cell Reagents

NEW YORK, April 21 (GenomeWeb News) - Serologicals said today that its Chemicon International subsidiary has signed an agreement with the AustralianStemCellCenter that will allow Chemicon exclusive rights to commercialize, market, and distribute stem cell reagents developed by ASCC worldwide.

 

Initial products from Chemicon will include a stem cell isolation kit, various proteins, and antibodies. ASCC will assist Chemicon in new product development in the research reagent area. In exchange, Chemicon said it will make an in-kind contribution of research tools for use by ASCC scientists, as well as contribute funds, products, and technical expertise to ASCC's recently launched stem cell training program.

 

Further details were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.